Editorial on the use of immunotherapy in renal-cell carcinoma

• Verfasst von: Menzer, Christian [VerfasserIn]
• Verfasst von: Grüllich, Carsten [VerfasserIn]
• Verfasst von: Hassel, Jessica C. [VerfasserIn]
• Titel: Editorial on the use of immunotherapy in renal-cell carcinoma
• Titelzusatz: promising results in combination therapy with ipilimumab and nivolumab
• Verf.angabe: Christian Menzer, Carsten Gruellich, Jessica C. Hassel
• E-Jahr: 2017
• Jahr: Sep 11, 2017
• Umfang: 4 S.
• Teil: volume:6
• Teil: year:2017
• Teil: supplement:Supplement 7
• Teil: pages:S1208-S1211
• Teil: extent:4
• Fussnoten: Gesehen am 26.09.2018
• Titel Quelle: Enthalten in: Translational cancer research
• Ort Quelle: Shatin : AME Publishing Company, 2012
• Jahr Quelle: 2017
• Band/Heft Quelle: 6(2017), Supplement 7, Seite S1208-S1211
• ISSN Quelle: 2219-6803
• DOI: doi:10.21037/tcr.2017.09.23
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1581320272

Abstract

During the last decades different immunotherapies have been used in the treatment of cancer without great success. However, stimulation of the immune system seems reasonable as there are immunogenic tumors such as melanoma and renal cell carcinoma which are known to rarely spontaneously regress when the immune system of the patient regains the ability to control the cancer (1). Multiple immune escape mechanisms are described which might be targeted by immunotherapies. The aim of all approaches is to enable the immune system to again recognize cancer antigens and eliminate the tumor cells (2). In contrast to chemotherapies and targeted therapies, immunotherapies thereby have the chance to lead to durable responses.